PRMA Consulting || Improving Pharmaceutical Market Access in Asia-Pacific
Agilent SLIMS
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

A Breakthrough Therapy Discovered for Polycythemia Vera (PV)

Rusfertide, a breakthrough therapy discovered for the treatment of patients with Polycythemia Vera (PV).

Rusfertide reduces the erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leucocytosis. Rusfertide which is a natural hormone mimeticis supposed to be the first non-cytoreductive therapeutic drug for PV.

Rusfertide in PV is considered to be a serious disease where the need for different and better treatment options is clear and pressing.

Studies have shown patients when treated with rusfertide, were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent, reverse iron deficiency, and experience symptom improvements.

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV).

Latest Issue
Get instant
access to our latest e-book
Saving Money, Saving Time In Pharma Operations Thermo Fisher Scientific || Revolutionize your mAb manufacturing Kerry || Webinar || Coatings Change Control Webinar || Recording-Webinar Rousselot || X-PureĀ® GelMA Meco - 90 years Medical Fair Thailand 2022